Therapy for Triple Receptor-Negative Breast Cancer with Residual Invasive Cancer or Positive Lymph Nodes

Status: open

18-002 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834

Description

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. IRB Number 18-002

Sponsors

This trial is sponsored by SWOG.

Providers Associated With This Trial

    Principle Investigator

    This link will open in a new tab or window.